UPDATE 1-Spain's PharmaMar sales rise on demand for cancer treatments [Reuters]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Reuters
the first half from the same period last year, when it had booked a large upfront licence payment. The company, which develops anti-tumour drugs from sea products, said its sales rose 24% to 65.0 million euros ($77.27 million) over the period, boosted by demand for cancer drugs. However, its net profit shrank to 43.2 million euros from a year earlier, helped by an advance 181 million euro payment received from Jazz Pharmaceuticals under a licence deal in the first quarter of 2020. The company's oncology division grew 33% in the January-June period to 62.5 million euros, boosted by European sales of a small-cell lung cancer drug Zepzelca, as well as stable performance of Yondelis, a drug to treat soft-tissue sarcoma and ovarian cancer. Sales in the group's diagnostics business continued to falter due to lower demand and falling prices for COVID-19 tests, due the rollout of vaccination campaigns and stockpiling at health centres. PharmaMar's R&D spending increased by 19.2% to
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Cancer and the Combination Approach [Yahoo! Finance]Yahoo! Finance
- AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING [Yahoo! Finance]Yahoo! Finance
- Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $190.00. They now have an "overweight" rating on the stock.MarketBeat
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.MarketBeat
JAZZ
Earnings
- 2/28/24 - Beat
JAZZ
Sec Filings
- 3/8/24 - Form 4
- 3/7/24 - Form 4
- 3/7/24 - Form 4
- JAZZ's page on the SEC website